Who
Robert Paul Smith Jr.
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Gossamer Bio.
In numbers
- Trades disclosed
- 18
- Buys
- 1
- Sells
- 0
- Bought
- $15K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Dec 2023
- Last trade
- 24 Aug 2026
- Last filed
- 26 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,800,051 at $0.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,800,051 at $0.00 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —562,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —572,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —562,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —562,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —572,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —562,500 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —572,000 | filing |
| 19 Mar 2026filed 20 Mar 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —572,000 | filing |
| 2 Jan 2026filed 5 Jan 2026 | GOSS Gossamer BioBiotechnology | SEC FORM 4 Code A | —93,750 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —562,500 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —562,500 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | GOSS Gossamer BioBiotechnology | SEC FORM 4 Code A | —93,750 at $0.00 | filing |
| 1 Oct 2025filed 2 Oct 2025 | GOSS Gossamer BioBiotechnology | SEC FORM 4 Code A | —162,500 at $0.00 | filing |
| 4 Mar 2025filed 6 Mar 2025 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —572,000 at $0.00 | filing |
| 17 Jun 2024filed 20 Jun 2024 | GOSS Gossamer BioBiotechnology | SEC FORM 4 Bought | $15K25,000 at $0.60 | filing |
| 4 Dec 2023filed 5 Dec 2023 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500,000 at $0.00 | filing |
News
Chardan Capital Begins Coverage on Gossamer Bio (NASDAQ:GOSS)GOSS · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Robert Paul Smith Jr.; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.